Unusual subtypes of prostate cancer

Modern Pathology

Volumn 17, Issue 3, 2004, Pages 316-327

  Grignon, David J ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Basaloid carcinoma; Prostate gland; Small cell carcinoma; Squamous cell carcinoma; Urothelial carcinoma; Variants

Indexed keywords

ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; CANCER CLASSIFICATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MUCINOUS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CARCINOMA; REVIEW; SIGNET RING CARCINOMA; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; ADENOCARCINOMA; CLASSIFICATION; MALE; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 7444243188     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800052     Document Type: Review

References (110)

1. Randolph TL, Amin MB, Ro JY, et al. Histologic variants of adenocarcinoma and other carcinomas of the prostate: pathologic criteria and clinical significance. Mod Pathol 1997;10:612-629.
2. Gleason DF. Classification of prostatic carcinoma. Cancer Chemother Rep 1966;50:125-128.
3. Amin MB, Grignon DJ, Humphrey PA, et al. Gleason Grading of Prostate Cancer: A Contemporary Approach. Lippincott, Williams & Wilkins: Philadelphia, PA, 2004.
4. Melicow MM, Pachter MR. Endometrial carcinoma of the prostatic utricle (uterus masculinus). Cancer 1976;20:1715-1721.
5. Melicow MM, Tannenbaum M. Endometrial carcinoma of uterus masculinus (prostatic utricle): report of 6 cases. J Urol 1971;106:892-902.
6. Zaloudek C, Williams JW, Kempson RL. 'Endometrial' adenocarcinoma of the prostate: a distinctive tumor of probable prostatic ductal origin. Cancer 1976;37:2255-2262.
7. Bostwick DG, Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features. Am J Surg Pathol 1985;9:595-609.
8. Epstein JI, Woodruff JM. Adenocarcinoma of the prostate with endometrioid features: a light microscopic and immunohistochemical study of 10 cases. Cancer 1986;57:111-119.
9. Ro JY, Ayala AG, Wishnow KI, et al. Prostatic ductal adenocarcinoma with endometrioid features: immunohistochemical and electron microscopic study. Semin Diagn Pathol 1988;5:301-311.
10. Christensen WN, Steinberg C, Walsh PC, et al. Prostatic duct adenocarcinoma: findings at radical prostatectomy. Cancer 1991;67:2118-2124.
11. Millar EKA, Sharma NK, Lessells AM. Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathologic study of 16 cases. Histopathology 1996;29:11-19.
12. Oxley JD, Abbot CD, Gillatt DA, et al. Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study. Br J Urol 1998;81:109-115.
13. Bock BJ, Bostwick DG. Does prostatic ductal adenocarcinoma exist? Am J Surg Pathol 1999;23:781-785.
14. Dawkins HJ, Sellner LN, Turbett GN, et al. Distinction between intraductal carcinoma of the prostate (IDC-P), high grade dysplasia (PIN) and invasive prostatic adenocarcinoma, using molecular markers of cancer progression. Prostate 2000;44:265-270.
15. Humphrey PA. Variants of Prostatic Carcinoma in Prostate Pathology. ASCP Press: Chicago, IL, 2003.
16. Brinker DA, Potter SR, Epstein JI. Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol 1999;23:1471-1479.
17. Gleason DF. Histologic grading of prostatic carcinomas. In: Bostwick DG (ed). Pathology of the Prostate. Churchill Livingstone: New York, NY, 1990.
18. Bostwick DG. Grading of prostate cancer. Am J Clin Pathol (Suppl) 1994;102:S38-S56.
19. Epstein JI, Yang XJ. Prostate Biopsy Interpretation. Lippincott, Williams & Wilkins: Philadelphia, PA, 2002.
20. Samaratunga H, Mahendra S. Distribution pattern of basal cells detected by cytokeratin 34betaE12 in primary prostatic ductal adenocarcinoma. Am J Surg Pathol 1997;21:435-440.
21. Epstein JI, Lieberman PH. Mucinous adenocarcinoma of the prostate gland. Am J Surg Pathol 1985;9:299-304.
22. Dhom G. Unusual prostatic carcinomas. Pathol Res Pract 1990;186:28-36.
23. Ro JY, Grignon DJ, Ayala AG, et al. Mucinous adenocarcinoma of the prostate: immunohistochemical studies. Hum Pathol 1990;21:593-600.
24. McNeal JE, Alroy J, Villers A, et al. Mucinous differentiation in prostatic adenocarcinoma. Hum Pathol 1991;22:979-988.
25. Teichman JMH, Shabaik A, Demby AM. Mucinous adenocarcinoma of the prostate and hormone sensitivity. J Urol 1994;151:701-702.
26. Saito S, Iwaki H. Mucin-producing carcinoma of the prostate: review of 88 cases. Urology 1999;54:141-144.
27. Ro JY, Grignon DJ, Troncoso P, et al. Mucin in prostatic adenocarcinoma. Semin Diagn Pathol 1988;5:273-283.
28. Saez C, Japon MA, Conde AF, et al. Sialomucins are characteristically O-acetylated in poorly differentiated and colloid prostatic adenocarcinoma. Mod Pathol 1998;11:1193-1197.
29. Van de Voorde W, Van Poppel HP, Haustermans K, et al. Mucin-secreting adenocarcinoma of the prostate with neuroendocrine differentiation and Paneth-like cells. Am J Surg Pathol 1994;18:200-207.
30. Tran TA, Jennings TA, Ross JS, et al. Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy. Am J Surg Pathol 1998;22:347-354.
31. Giltman LI. Signet ring cell adenocarcinoma of the prostate. J Urol 1981;126:134-135.
32. Ro JY, El-Naggar A, Ayala AG, et al. Signet ring cell carcinoma of the prostate: electron-microscopic and immunohistochemical studies of eight cases. Am J Surg Pathol 1988;12:453-460.
33. Hejka AG, England DM. Signet ring cell carcinoma of prostate: immunohistochemical and ultrastructural study of a case. Urology 1989;24:155-158.
34. Guerin D, Hasan N, Keen CE. Signet ring cell differentiation in adenocarcinoma of the prostate: a study of five cases. Histopathology 1993;22:367-371.
35. Smith C, Feddersen RM, Dressler L, et al. Signet ring cell adenocarcinoma of prostate. Urology 1994;43:397-400.
36. Leong FJ, Leong AS, Swift J. Signet-ring carcinoma of the prostate. Pathol Res Pract 1996;192:1232-1238.
37. Torbenson M, Dhir R, Nangia A, et al. Prostatic carcinoma with signet ring cells: a clinicopathologic and immunohistochemical analysis of 12 cases, with review of the literature. Mod Pathol 1998;11:552-559.
38. Kuroda N, Yamasaki I, Nakayama H, et al. Prostatic signet-ring cell carcinoma: case report and literature review. Pathol Int 1999;49:457-461.
39. Schned AR. Artifactual signet-ring cells [letter]. Am J Surg Pathol 1987;11:736-737.
40. Alguacil-Garcia A. Artifactual changes mimicking signet ring cell carcinoma of transurethral prostatectomy specimens. Am J Surg Pathol 1986;10:795-800.
41. Mott LJM. Squamous cell carcinoma of the prostate: report of 2 cases and review of the literature. J Urol 1979;121:833-836.
42. Miller VA, Reuter V, Scher HI. Primary squamous cell carcinoma of the prostate after radiation and seed implantation for adenocarcinoma. Urology 1995;46:111-113.
43. Rahmanou F, Koo J, Marinbakh AY, et al. Squamous cell carcinoma at the prostatectomy site: squamous differentiation of recurrent prostate carcinoma. Urology 1999;54:744.
44. Okada E, Kamizaki H. Primary squamous cell carcinoma of the prostate. Int J Urol 2000;7:347-350.
45. Imamura M, Nishiyama H, Ohmori K, et al. Squamous cell carcinoma of the prostate without evidence of recurrence 5 years after operation. Urol Int 2000;65:122-124.
46. Nabi G, Ansari MS, Singh I, et al. Primary squamous cell carcinoma of the prostate: a rare clinicopathologic entity. Report of 2 cases and review of the literature. Urol Int 2001;66:216-219.
47. Majeed F, Javed TA, Khan AU, et al. Primary squamous cell carcinoma of the prostate: a novel chemotherapy regimen. J Urol 2002;168:640.
48. Al Adnani MS. Schistosomiasis, metaplasia and squamous cell carcinoma of the prostate: histogenesis of the squamous cancer cells determined by localization of specific markers. Neoplasma 1985;32:613-622.
49. Saito R, David BK, Ollipally EP. Adenosquamous carcinoma of the prostate. Hum Pathol 1984;15:87-89.
50. Devaney DM, Dorman A, Leader M. Adenosquamous carcinoma of the prostate: a case report. Hum Pathol 2001;22:1046-1050.
51. Gattuso P, Carson HJ, Candel A, et al. Adenosquamous cell carcinoma of the prostate. Hum Pathol 1995;26:123-126.
52. Bassler. Jr TJ, Orozco R, Bassler IC, et al. Adenosquamous carcinoma of the prostate: case report with DNA analysis, immunohistochemistry and literature review. Urology 1999;53:832-834.
53. Frankel. Jr KC. Adenoid cystic carcinoma of the prostate: report of a case. Am J Clin Pathol 1974;62:639-645.
54. Gilmour AM, Bell TJ. Adenoid cystic carcinoma of the prostate. Br J Urol 1986;58:105-106.
55. Grignon DJ, Ro JY, Ordonez NG, et al. Basal cell hyperplasia, adenoid basal cell tumor and adenoid cystic carcinoma of the prostate gland: an immunohistochemical study. Hum Pathol 1988;19:1425-1433.
56. Young RH, Frierson RH, Mills SE, et al. Adenoid cystic-like tumor of the prostate gland: a report of two cases and review of the literature on adenoid cystic carcinomas of the prostate. Am J Clin Pathol 1988;89:49-56.
57. Denholm SW, Webb JN, Howard GCW, et al. Basaloid carcinoma of the prostate gland: histogenesis and review of the literature. Histopathology 1992;20:151-155.
58. Deveraj LT, Bostwick DG. Atypical basal cell hyperplasia of the prostate: immunophenotypic profile and proposed classification of basal cell proliferations. Am J Surg Pathol 1993;7:645-659.
59. Van Renterghem K, Mattelaer J, Billiet I. Adenoid cystic carcinoma of the prostate. Acta Urol Belg 1994;62:69-70.
60. Yang XJ, McEntee M, Epstein JI. Distinction of basaloid carcinoma of the prostate from benign basal cell lesions by immunohistochemistry for bcl-2 and Ki-67. Hum Pathol 1998;29:1447-1450.
61. Terris MK. The appearance of adenoid cystic carcinoma of the prostate on transrectal ultrasonography. BJU Int 1999;83:875-876.
62. Minei S, Hachiya T, Ishida H, et al. Adenoid cystic carcinoma of the prostate: a case report with immunohistochemical and in situ hybridization staining for prostate-specific antigen. Int J Urol 2001;8: S41-S44.
63. Schmid HP, Semjenow A, Eltze E, et al. Late recurrence of adenoid cystic carcinoma of the prostate. Scand J Urol Nephrol 2002;36:158-159.
64. Young RH, Srigley JR, Amin MB. Variants of prostatic adenocarcinoma, other primary carcinomas of prostate and secondary carcinoma. In: Tumors of the Prostate Gland, Seminal Vesicles, Male Urethra and Penis. Armed Forces Institute of Pathology: Washington, DC, 2000, pp 217-255.
65. Wick MR, Young RH, Malvesta R, et al. Prostatic carcinosarcomas: clinical, histologic and immunohistochemical data on two cases with a review of the literature. Am J Clin Pathol 1989;92:131-139.
66. Shannon RL, Ro JY, Grignon DJ, et al. Sarcomatoid carcinoma of the prostate: a clinicopathologic study of 12 cases. Cancer 1992;69:2676-2682.
67. Lauwers GY, Schevchuk M, Armenakas N, et al. Carcinosarcoma of the prostate. Am J Surg Pathol 1993;7:342-349.
68. Dundore PA, Cheville JC, Nascimento AG, et al. Carcinosarcoma of the prostate: report of 22 cases. Cancer 1995;76:1035-1042.
69. Koleski FC, Turk TM, Wojcik EM, et al. Carcinosarcoma of the prostate. World J Urol 1999;17:316-318.
70. Delahunt B, Eble JN, Nacey JN, et al. Sarcomatoid carcinoma of the prostate: progression from adenocarcinoma is associated with p53 overexpression. Anticancer Res 1999;19:4279-4283.
71. Renshaw AA, Granter SR. Metastatic Sarcomatoid, and PSA- and PAP-negative prostatic carcinoma: diagnosis by fine needle aspiration. Diagn Cytopathol 2000;23:199-201.
72. Poblet E, Gomez-Tierno A, Alfaro L. Prostatic carcinosarcoma: a case originating in a previous ductal adenocarcinoma of the prostate. Pathol Res Pract 2000;196:569-572.
73. Canfield SE, Gans TH, Unger P, et al. Postradiation prostatic sarcoma: de novo carcinogenesis or dedifferentiation of prostatic adenocarcinoma? Tech Urol 2001;7:294-295.
74. Bostwick DG, Adlakha K. Lymphoepithelioma-like carcinoma of the prostate. J Urol Pathol 1994;12:319-325.
75. Di Sant'Agnese PA. Divergent neuroendocrine differentiation in prostatic carcinoma. Semin Diagn Pathol 2000;17:149-161.
76. Adlakha K, Bostwick DG. Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases. Hum Pathol 1994;25:135-139.
77. Tetu B, Ro JY, Ayala AG, et al. Small cell carcinoma of prostate: a clinicopathologic study of 20 cases. Cancer 1987;59:1803-1809.
78. Moore SR, Reinberg Y, Zhang G. Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy. Urology 1992;39:411-416.
79. Amato RJ, Logothetis CJ, Hallinan R, et al. Chemotherapy for small cell carcinoma of prostatic origin. J Urol 1992;147:935-937.
80. Oesterling JE, Hauzear CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 1992;147:804-809.
81. Rubenstein JH, Katin MJ, Mangano MM, et al. Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol 1997;20:376-380.
82. Mackey JR, Au HJ, Hugh J, et al. Genitourinary small cell carcinoma: determination of clinical therapeutic factors associated with survival. J Urol 1998;159:1624-1629.
83. Schwartz LH, LaTrenta LR, Bonaccio E, et al. Small cell and anaplastic prostate cancer: correlation between CT findings and prostate-specific antigen level. Radiology 1998;208:735-738.
84. Helpap B, Kollerman J. Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch 1999;434:385-391.
85. Tanaka M, Suzuki Y, Takaoka K, et al. Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 2001;8:431-436.
86. Lopez Cubillana P, Martinez Barba E, Prieto A, et al. Oat-cell carcinoma of the prostate: diagnosis, prognosis and therapeutic implications. Urol Int 2001;67:209-212.
87. Papandreou CN, Daliana DD, Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20:3072-3080.
88. Ro JY, Tetu B, Ayala AG, et al. Small cell carcinoma of the prostate: immunohistochemical and electron microscopic studies of 18 cases. Cancer 1987;59:1803-1809.
89. Greene LF, O'Dea MF, Dockerty MB. Primary transitional cell carcinoma of the prostate. J Urol 1976;116:235-237.
90. Johnson DE, Hogan JM, Ayala AG. Transitional cell carcinoma of the prostate. Cancer 1972;29:287-293.
91. Greene LF, Mulcashy JJ, Warren MM, et al. Primary transitional cell carcinoma of the prostate. J Urol 1973;110:235-237.
92. Mahadevia PS, Koss LG, Tar IJ. Prostatic involvement in bladder cancer: prostate mapping in 20 cystoprostatectomy specimens. Cancer 1986;58:2095-2102.
93. Nixon RG, Chang SS, Lafleur BJ, et al. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol 2002;167:502-505.
94. Wood. Jr DP, Montie JE, Pontes JE, et al. Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. J Urol 1989;141:346-349.
95. Ende N, Woods LP, Shelley HS. Carcinoma originating in ducts surrounding the prostatic urethra. Am J Clin Pathol 1963;40:183-189.
96. Karpas CM, Moumgis B. Primary transitional cell carcinoma of the prostate: possible pathogenesis and relationship to reserve cell hyperplasia of prostatic periurethral ducts. J Urol 1969;101:201-205.
97. Ullmann AS, Ross OA. Hyperplasia, atypism and carcinoma in situ in prostatic periurethral glands. Am J Clin Pathol 1967;747:497-504.
98. Razvi M, Fifer R, Berkson B. Occult transitional cell carcinoma of the prostate presenting as skin metastases. J Urol 1975;113:734-735.
99. Oliai BR, Kahane H, Epstein JI. A clinicopathologic analysis of urothelial carcinomas diagnosed on prostate needle biopsies. Am J Surg Pathol 2001;25:794-801.
100. Sawczuk I, Tannenbaum M, Olson CA, et al. Primary transitional cell carcinoma of prostate periurethral ducts. Urol 1985;25:339-343.
101. Takashi MS, Sakata T, Nagai T, et al. Primary transitional cell carcinoma of prostate: case with lymph node metastasis eradicated by neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-vac) therapy. Urology 1990;36:96-98.
102. AJCC. AJCC Cancer Staging Manual, 6th edn, Springer: New York, 2002.
103. Cheville JC, Dundore PA, Bostwick DG, et al. Transitional cell carcinoma of the prostate: clinicopathologic study of 50 cases. Cancer 1998;82:703-707.
104. Nicolaisen GS, Williams RD. Primary transitional cell carcinoma of the prostate. Urology 1984;24:544-549.
105. Smith BD, Flegel G. Primary transitional cell carcinoma of the prostate: report of two cases. J Am Osteopath 1982;82:547-548.
106. Tannenbaum M. Transitional cell carcinoma of the prostate. Urology 1975;5:674-678.
107. Goebbels R, Amberger L, Wernert N, et al. Urothelial carcinoma of the prostate. Appl Pathol 1985;3:242-254.
108. Cheville JC. Urothelial carcinoma of the prostate: an immunohistochemical comparison with high grade prostatic adenocarcinoma and review of the literature. J Urol Pathol 1998;9:141-154.
109. Bodner DR, Cohen JK, Resnick MI. Primary transitional cell carcinoma of the prostate. J Urol 1986;92:121-122.
110. Laplante M, Brice M. The upper limits of hopeful application of radical cystectomy for vesical carcinoma: does nodal metastasis always indicate incurability? J Urol 1973;109:261-264.